US SEC Filings Daily Market Digest — August 25, 2026

25-08-2026

NextEra Energy (NEE) is voluntarily supplementing its joint proxy statement/prospectus for its planned acquisition of Dominion Energy to address shareholder demand letters alleging disclosure deficiencies. The supplemental disclosures provide additional details on the merger background, including discussions with Party A, and Lazard's financial analyses. NextEra Energy maintains that the original disclosures comply with applicable law and that the allegations are without merit; the voluntary supplementation is intended to moot the claims and avoid any delay in closing.

• · On March 26, 2026, Mr. Blue called Party A's CEO, informing him Dominion Energy's board required a higher premium from Party A but was prepared to proceed with diligence subject to a non-disclosure and standstill agreement.
• · On March 27, 2026, a Non-Disclosure and Standstill Agreement with Party A was executed, including a standstill restriction that expired upon Dominion Energy's entry into a definitive agreement.
• · The supplemental disclosures detail Lazard's sum-of-the-parts DCF and company comparables analyses for both NextEra Energy and Dominion Energy, including the calculation of net debt (including finance leases, preferred equity, noncontrolling interest, less cash/equivalents and equity method investments).
• · Lazard used a discount rate range for each segment based on estimated WACC and selected exit multiples based on professional judgment.
• · Comparable analysis for NextEra Energy's Premium Utility Peers (2026E/2027E Price/Adjusted EPS) showed means of 20.5x/18.8x and top quartiles of 21.0x/19.4x; Premium Independent Power Producer Peers (2026E/2027E EV/Adjusted EBITDA) showed means of 12.6x/11.5x and top quartiles of 13.5x/12.4x.
• · Comparable analysis for Dominion Energy's Utility Peers (2026E/2027E Price/Adjusted EPS) showed means of 18.5x/17.2x and top quartiles of 19.2x/17.7x; Premium Independent Power Producer Peers (2026E/2027E EV/Adjusted EBITDA) had the same mean and top quartile as NextEra Energy's IPP peer group.

25-08-2026

On August 20, 2026, Regenerative Medical Technology Group Inc. held an investor video call where management provided business updates. CEO Dave Christensen noted that Q1 2026 revenue grew 90% year-over-year and Q2 revenue quadrupled versus the prior year, driven by ISSCA education and Cellgenic product sales. However, the company carries significant debt and growing interest expense from financing its expansion, and CEO cautioned that the timing for a Nasdaq uplisting cannot be guaranteed. The call also highlighted recent milestones including a new laboratory and a first-of-its-kind biologics license in Argentina, but no new financial figures or specific guidance were disclosed.

• · The company held an investor video call on August 20, 2026; a transcript was furnished as Exhibit 99.1.
• · CEO mentioned helping a company lead an IPO in 2018 and described the Nasdaq uplisting checklist requirements.
• · The company carries significant liabilities and growing interest expense from financing the acquisition of Global Stem Cell Group and other expansion.
• · The BKFC partnership makes RMTG the league's official regenerative medicine partner for treating fighters.
• · Over 478 doctors attended the previous September annual event.
• · The company is opening a new laboratory and obtained a first-of-its-kind biologics license in Argentina.
• · Affiliate model provides recurring revenue through a membership-like tier system for doctors.
• · The Cancun facility is located in a medical destination central area with world-class facilities.

25-08-2026

Hypersonics and critical munitions company Ursa Major has entered a definitive business combination agreement with SPAC Bleichroeder Acquisition Corp. III (BCCQU) to go public at a pre-money valuation of ~$1.6B and a post-transaction equity valuation of ~$2.3B. The deal is backed by at least $350M in PIPE commitments anchored by Inflection Point Asset Management, with ~$110M funded at signing and up to $345M in additional proceeds depending on redemptions. Closing is expected in Q1 2027, subject to shareholder and regulatory approvals, and the combined company will trade on Nasdaq.

• · Combined company to be renamed Inflection Point Mach X Bleichroeder Corp. and trade on Nasdaq under ticker IPXX.
• · Ursa Major has conducted more than 5,500 ground tests and 140,000 seconds of testing; its engines have powered over a dozen successful hypersonic missions.
• · The PIPE is anchored by Inflection Point and includes new institutional investors and existing Ursa Major investors, including XN.
• · Near-term capital will support expansion of the Galeton, Colorado site from a solid rocket motor test site into a large-scale production campus.
• · Inflection Point has raised more than $10B of capital across eight transactions.
• · Cantor Fitzgerald is acting as lead placement agent and lead financial advisor to Bleichroeder; Moelis is joint placement agent and exclusive capital markets advisor to Ursa Major.
• · SPAC sponsor Inflection Point previously took Intuitive Machines and USA Rare Earth public.

25-08-2026

OneConstruction Group Ltd issued a 6-K announcement addressing recent volatility in its ordinary shares and social media stock promotion. The company confirmed it is unaware of any undisclosed corporate developments or material non-public information that would account for the trading activity, and stated that its operational fundamentals remain stable since its Form 20-F filing on July 23, 2026. The company also clarified that it has not engaged or compensated any third parties for promotional activities, and cautioned investors to rely only on official SEC filings.

• · The company's ordinary shares have experienced fluctuations in price and daily trading volume over the past months.
• · The company filed its annual report on Form 20-F on July 23, 2026.
• · The company advises investors that statements on social media are not authorized, approved, endorsed, or verified by the company.
• · The company states that neither it nor its officers, directors, employees, or affiliates have engaged or compensated third parties for promotional activities.
• · Investors are cautioned that sudden market fluctuations and speculative trading can result in severe or total capital loss.

25-08-2026

Citi Trends reported strong Q2 fiscal 2026 results with total sales up 10.9% to $211.6M and comparable store sales growth of 10.5%, marking the eighth consecutive quarter of comparable sales growth. However, the company posted a net loss of $0.9M in Q2 compared to net income of $3.8M in the prior-year quarter (which included an $11.0M gain on sale of a building). For the first half of fiscal 2026, net income improved to $6.8M from $4.7M and adjusted EBITDA surged to $19.4M from $5.3M. The company raised its full-year outlook, now expecting comp sales growth of 9%-11% and adjusted EBITDA of $38M-$42M.

• · Q2 2026 SG&A expense of $82.3M (38.0% of sales) vs $78.9M (40.6% of sales) in Q2 2025
• · Adjusted EBITDA in Q2 2026 was $5.5M vs a loss of $1.1M in Q2 2025
• · Q2 2026 included a $0.5M adjusted net income vs an adjusted net loss of $5.4M in Q2 2025
• · First half 2026 cash flow from operations not separately disclosed; cash balance $55.9M
• · The company plans to open 20 new stores in fiscal 2026 (down from prior estimate of 25) and add 10-15 additional remodels beyond the 50 already planned
• · Capital expenditures for fiscal 2026 guided at $35M-$40M
• · Company maintains no debt and no borrowings under its $75M credit facility
• · Store count net increased by 3 (4 opened, 1 closed) during Q2

25-08-2026

Marzetti Company reported mixed Q4 FY2026 results: consolidated net sales declined 2.2% to $465.0M, but adjusted sales (excluding a non-core TSA) rose 0.4%. Gross profit hit a record $114.0M with margin up 220 bps to 24.5%, while SG&A jumped $12.3M to $74.3M due to acquisition costs. Adjusted diluted EPS grew 9.0% to $1.46, but Retail volume fell 1.7% and Foodservice volume declined 4.1% (core volume flat). The company completed the Bachan’s acquisition on May 1, 2026, contributing $15.4M in incremental Retail sales.

• · Interest expense rose to $1.8M in Q4 FY2026 from $0 in prior year due to $200M term loan for Bachan's acquisition.
• · Retail volume declined 1.7% despite 0.9% net sales growth, indicating price/mix improvement.
• · Foodservice core volume (excl. TSA) was essentially flat (+0.1%), while reported volume fell 4.1%.
• · Bachan's contributed 640 bps of Retail net sales growth and 520 bps of Retail volume growth.
• · FY2026 adjusted diluted EPS grew only 1.6% to $6.83 from $6.72, a much slower pace than Q4's 9.0% growth.
• · The company flagged potential headwinds from Cyclospora outbreak and moderate inflation in FY2027.
• · Cash returned to shareholders in FY2026: $108.8M dividends + $36.3M stock buybacks.

25-08-2026

Advus Financial Partners, LLC filed its 13F-HR for the quarter ended March 31, 2024, reporting a diversified equity and fixed-income portfolio valued at approximately $323.5 million. The top holdings are dominated by iShares ETFs, with the largest positions in the Core S&P 500 ETF ($39.6M), Core S&P Total Stock Market ETF ($29.5M), and MSCI ACWI ex US ETF ($22.0M). The filing shows a broad, multi-asset strategy with significant exposure to U.S. large-cap, international, and fixed-income ETFs, alongside individual stocks like Apple ($7.2M), Microsoft ($5.1M), and Amazon ($3.2M).

• · The filing reports 202 individual holdings as of March 31, 2024.
• · The top 10 holdings account for approximately $188.5 million, or 58% of the total portfolio.
• · The portfolio is heavily weighted toward iShares ETFs, which represent about 60% of total holdings.
• · Individual stock holdings include major tech, financial, healthcare, and consumer companies.
• · The filing was submitted on August 25, 2026, for the quarter ended March 31, 2024, indicating a significant delay in reporting.
• · The filing was signed by Rodrigo Diaz, Compliance Analyst.

25-08-2026

Davey Tree Expert Co reported record Q2 2026 revenue of $518.9M, up 1.3% YoY, driven by Residential/Commercial growth of 2.5%, while Utility Services revenue was flat. However, profitability declined sharply: income from operations fell to $42.5M from $49.1M, and net income dropped to $24.7M from $32.8M, due to cost pressures, reduced storm activity, and challenging market conditions. For the first half of 2026, revenue rose 0.8% to $954.7M, but net income fell to $14.0M from $29.5M, reflecting headwinds from consumer softness, inflation, tariff volatility, and higher interest expense.

• · Residential/Commercial segment revenue was $423.0M in first half 2026, a slight decrease from prior year, with growth in residential offset by lower Commercial Landscape Services (CLS) activity.
• · Utility segment revenue was $529.5M in first half 2026, up from $522.0M in 2025.
• · Net working capital improved to $194.7M as of July 4, 2026, from $130.1M at year-end 2025.
• · Total assets increased to $1,574.7M from $1,496.8M at year-end 2025.
• · Total equity decreased to $335.4M from $356.6M at year-end 2025.
• · Dividend increased to $0.03 per share for Q3 2026 from $0.025 in Q3 2025.
• · Stock price per MPI valuation was $28.90 as of June 30, 2026, up 4.7% from $27.60 at year-end 2025.
• · Weighted average diluted shares outstanding decreased to 39.6M in Q2 2026 from 42.2M in Q2 2025.

25-08-2026

On August 25, 2026, Natixis Commercial Mortgage Securities LLC issued $377,960,000 in Commercial Mortgage Pass-Through Certificates (Series 2026-M1) backed by 20 fixed-rate mortgage loans on 21 multifamily properties. The offering included publicly offered and privately placed certificates, with net proceeds of approximately $385,020,823 used to purchase the mortgage loans from Natixis Real Estate Capital LLC. The transaction also satisfied credit risk retention requirements through the retention of horizontal residual interest certificates valued at approximately $25,486,419 (5.72% of aggregate fair value).

• · The registration statement (file no. 333-274151) was originally declared effective on September 14, 2023.
• · No underwriting discounts and commissions or finder's fees were paid by the Registrant.
• · The Publicly Offered Certificates were offered by the Underwriters for sale to the public in negotiated transactions or otherwise at varying prices determined at the time of sale.
• · The legal opinion and tax opinion were rendered by Hogan Lovells Cadwalader US LLP, dated August 25, 2026.
• · The Retaining Sponsor (NREC) satisfied credit risk retention by having D2-Natixis Retention Holder, LLC purchase and hold the HRR Certificates.

25-08-2026

Vyome Holdings reported Q2 2026 results with cash increasing to $7.9M from $5.0M at year-end 2025, and a net loss of $720,000 for the quarter. The company advanced its lead VT-1953 program with FDA feedback received and plans for a Type C meeting, and expanded its pipeline via an Impetis agreement for two JAK inhibitor assets. However, operating expenses more than doubled to $2.02M for the six-month period (from $702K), and revenue declined sharply to $58.5K from $248.5K, reflecting a mixed financial performance.

• · Total current assets were approximately $8.2 million as of June 30, 2026.
• · Total liabilities decreased to $1.86M from $2.74M at year-end 2025.
• · Net loss per share for Q2 2026 was approximately $0.10.
• · Phase 2 data for VT-1953 showed statistically significant improvements in malodor, impact on daily life, and lesion pain, with no treatment-emergent adverse events.
• · A Chinese patent was granted covering formulation and therapeutic use claims for VB-1953 topical gel for inflammatory acne.
• · The company has no debt, no preferred stock, and no toxic financing instruments.

25-08-2026

The filing is a Form 8-K by DraftKings Inc. reporting a material definitive agreement (Item 1.01), the creation of a direct financial obligation (Item 2.03), and a Regulation FD disclosure (Item 7.01). Specific financial terms, transaction details, and counterparties are not disclosed within the filing's metadata or summary. While the event signals a strategic transaction, the lack of quantified data prevents a directional assessment; both positive and negative implications remain unquantifiable.

• · The 8-K contains exhibits (Item 9.01) but their content is not described in the metadata.
• · The filing is dated August 25, 2026, and was filed on the same day.
• · The SEC filing number is 0001104659-26-100812 and the document size is 2 MB.

25-08-2026

Meritage Homes Corporation filed an 8-K on August 25, 2026, disclosing amendments to its Amended and Restated Bylaws. Key changes include reducing the stockholder ownership threshold to call a special meeting from 50% to 25% of voting power, and updating advance notice provisions for director nominations and stockholder proposals. The amendments also clarify voting procedures, including plurality voting in contested elections and proxy card color requirements.

• · Stockholder threshold to call a special meeting reduced from 50% to 25% of voting power.
• · Advance notice deadlines for stockholder proposals: notice must be delivered between 150th and 120th day prior to anniversary of prior year's proxy statement.
• · Plurality voting applies in director elections if number of nominees exceeds seats due to a stockholder nomination, unless the nomination is withdrawn or invalidated.
• · Stockholders soliciting proxies must use a non-white proxy card; white is reserved for Board of Directors.
• · Directors can be removed with cause by a majority vote of all votes entitled to be cast at a special meeting.

25-08-2026

Ryman Hospitality Properties issued $700 million in 6.250% Senior Notes due 2035 to help fund the $1.38 billion Grande Lakes Acquisition in Orlando. The balance of the purchase price will come from a $686 million common stock offering that closed August 12, 2026 (5,865,000 shares at $117.00 per share) and cash on hand. The indenture restricts borrowing, dividends, and asset sales, and if the acquisition is not completed, the notes are subject to a special mandatory redemption.

• · Interest on the Notes is payable February 15 and August 15 each year, beginning February 15, 2027; Notes mature February 15, 2035.
• · Issuers may redeem Notes before August 15, 2029 at 100% of principal plus make‑whole premium, and on/after August 15, 2029 at scheduled percentages (103.125% in 2029, 101.563% in 2030, 100% thereafter).
• · Issuers may redeem up to 40% of Notes before August 15, 2029 with equity offering proceeds at 106.250% of principal, provided 60% of original principal remains outstanding.
• · Upon a Change of Control Triggering Event, Issuers must offer to repurchase Notes at 101% of principal plus accrued interest.
• · The Indenture contains customary events of default, including nonpayment, breach of covenants, cross‑acceleration on other debt, failure to pay certain judgments, and bankruptcy/insolvency events.

25-08-2026

LGAM Private Credit LLC sold approximately 177,957 common units at $19.53 per unit for aggregate proceeds of about $3.5 million in an unregistered offering under Regulation S. The fund declared a regular distribution of $0.1383 per unit payable September 3, 2026. As of July 31, 2026, the company reported an estimated NAV of $243.4 million and $305.7 million in debt outstanding, with 99.2% of its $656.9 million portfolio in first lien debt and no new investment commitments during July.

• · The company had no new investment commitments during the period July 1, 2026 through July 31, 2026.
• · Top ten portfolio companies account for 18.1% of total par value; the largest is Banyan Software Holdings, LLC at 2.3%.
• · Largest industry exposure is Software at 19.1%, followed by Insurance Services at 10.3%.
• · The distribution of $0.1383 per unit will be payable on or around September 3, 2026 to unitholders of record as of August 31, 2026.
• · The company is an emerging growth company and has elected not to use the extended transition period for complying with new or revised financial accounting standards.

25-08-2026

Walter V. Klemp, Chairman, CEO, and President of Moleculin Biotech, Inc., filed a Schedule 13D disclosing beneficial ownership of 2,070,761 shares of common stock, representing 9.87% of the outstanding shares as of August 19, 2026. The filing details his recent purchase of 533,333 shares and warrants for $399,999.75 in a public offering, as well as his control over AnnaMed, Inc., which holds an additional 636 shares. No negative or flat metrics are present in this beneficial ownership disclosure.

• · The beneficial ownership limitation on the Series I Warrants was increased from 4.99% to 9.99% effective October 18, 2026.
• · The Series I Warrants have an exercise price of $0.75 per share, expire on August 3, 2031, and include an anti-dilution provision with a floor price of $0.21.
• · AnnaMed originally received 1,431,000 shares in 2015 for transferring an FDA IND application for Annamycin, which were reduced to 636 shares after three reverse stock splits.
• · Klemp participated in board approval of proposals for the 2026 annual meeting, including director elections, equity plan increase, elimination of supermajority voting, and a reverse stock split.

25-08-2026

REGENXBIO appointed Greg Ciongoli to its Board of Directors effective August 25, 2026, as the company prepares to become a global commercial organization with multiple late-stage pipeline catalysts. Concurrently, two long-serving independent directors, Jerry Karabelas (since 2015) and Jean Bennett (since 2021), retired from the Board. The changes reflect a strategic succession plan to balance scientific, clinical, commercial, and capital markets expertise.

• · Greg Ciongoli brings experience in biotechnology investing, capital allocation, and corporate strategy from his roles at Adiumentum Capital Management and previously The Baupost Group.
• · Mr. Ciongoli currently serves as Board Chairman of Atara Biotherapeutics and is a Board member at Zymeworks Inc.
• · The company's late-stage pipeline includes RGX-202 for Duchenne, ABBV-RGX-314 for wet AMD/diabetic retinopathy (with AbbVie), RGX-121 for MPS II, and RGX-111 for MPS I (with Nippon Shinyaku).
• · Thousands of patients have been treated with REGENXBIO's AAV platform, including those receiving Novartis' ZOLGENSMA.

25-08-2026

Fund 1 Investments, LLC disclosed a 9.9% beneficial ownership stake in Xponential Fitness, Inc. (XPOF), holding 4,170,610 Class A common shares as of August 25, 2026, with an aggregate purchase price of approximately $25.85 million. The reporting person, which serves as managing member of investment adviser Pleasant Lake Partners LLC, stated it believes the shares were undervalued and intends to engage with the board and management on operational and strategic opportunities. However, the filing also reveals significant recent trading activity, including large purchases and sales, and the use of cash-settled total return swaps and short put options, indicating an active and potentially activist investment approach.

• · Fund 1 Investments has sole voting and dispositive power over all 4,170,610 shares.
• · The reporting person disclaims beneficial ownership except for pecuniary interest.
• · Cash-settled total return swaps provide economic exposure to 2,161,006 notional shares (5.1% of outstanding).
• · Sold short 2,000,000 put options with $5 exercise price, expiring September 18, 2026.
• · Recent trading activity shows active buying and selling, with purchases at prices ranging from $4.88 to $7.12 per share.
• · The reporting person intends to engage in discussions with the board and management regarding operational and strategic opportunities to enhance stockholder value.
• · The reporting person may increase or decrease its position, engage in hedging or derivative transactions, or propose changes to capitalization, ownership structure, or board composition.
• · The reporting person has not been convicted in any criminal proceeding or been subject to any securities-related civil judgment in the last five years.
• · The shares were purchased with working capital of the Funds, which may include margin loans.

25-08-2026

Jones Financial Companies LLLP filed an S-4/A registration statement with the SEC on August 25, 2026, offering to exchange all outstanding Class A Interests for Class B Interests on a one-for-one basis at $1,000 per unit. As of August 14, 2026, there were 1,716,911.20 units of Class A Interests outstanding and zero Class B Interests; if all are exchanged, zero Class A and 1,716,911.20 Class B units would remain. The exchange is voluntary but subject to strict transfer restrictions, no public market, and mandatory redemption upon death, voluntary withdrawal, or Managing Partner notice.

• · The exchange offer is being made pursuant to a Schedule TO and Form S-4.
• · Class B Interests have no voting or management rights; holders must accept redemption upon death, voluntary withdrawal, or Managing Partner notice.
• · Interests are not listed on any stock exchange and cannot be transferred without Managing Partner consent, which is not expected to be given.
• · The Partnership operates in the U.S. and Canada through Edward Jones and EJ Canada, deriving revenue from fees, commissions, and asset-based fees.
• · The prospectus incorporates by reference the 2025 Form 10-K and subsequent Forms 10-Q and 8-K.

25-08-2026

Exyn Technologies CEO and Chairman Brandon Torres Declet resigned on August 19, 2026, after an internal investigation found he used a company credit card for approximately $286,000 in personal travel and other personal expenses, which were recorded as business expenses. The Board appointed COO Benjamin Williams as Interim CEO, effective immediately, and raised his base salary from $294,000 to $355,000, and named director Gregory McNeal as Non-Executive Chairman with an additional $35,000 cash retainer. Mr. Declet agreed to repay the expenses, forgo severance, and is subject to a non-disparagement and release agreement in exchange for the company forbearing from immediate legal action.

• · The internal investigation was previously disclosed in an amended Quarterly Report on Form 10-Q/A filed on August 19, 2026.
• · Mr. Declet's resignation was not over any disagreement with the company's operations, policies, or practices (other than the investigation matter).
• · Benjamin Williams previously served as interim CEO from June 2023 through November 2023.
• · Williams's employment remains at-will, and he is subject to a non-competition and non-solicitation covenant during employment and for six months after.
• · Mr. Declet will forfeit severance, option acceleration, or other special treatment of vested equity.

25-08-2026

Repligen Corporation (RGEN) is merging with BioLife Solutions, Inc. in a stock-and-cash transaction expected to close in Q4 2026. BioLife stockholders will receive Repligen common stock and cash consideration, and will own an estimated percentage of the combined company. The merger is subject to BioLife stockholder approval, antitrust clearance, and other customary conditions.

• · BioLife stockholders who do not vote in favor of the merger and meet strict procedural requirements may seek appraisal of their shares under Delaware law.
• · The merger is structured as a 'reorganization' under Section 368(a) of the Internal Revenue Code, generally resulting in gain recognition limited to cash received.
• · Conditions to closing include BioLife stockholder approval, HSR Act waiting period expiration, SEC effectiveness of the registration statement, and Nasdaq listing authorization.
• · BioLife's principal executive offices are in Bothell, Washington; Repligen is headquartered in Waltham, Massachusetts.
• · BioLife focuses on biopreservation media and cell processing for cell and gene therapy; Repligen provides bioprocessing technologies for biologic drug manufacturing.

25-08-2026

nCino, Inc. reported a strong turnaround for its fiscal Q2 2027 (three months ended July 31, 2026), with total revenue growing 8.2% YoY to $161.0M and net income attributable to nCino of $5.1M versus a net loss of $15.3M in the prior-year quarter. Subscription revenue rose 9.7% YoY to $143.5M, while professional services revenue declined 2.9% YoY to $17.5M. The company achieved operating income of $13.6M compared to an operating loss of $9.3M a year ago, driven by lower operating expenses. However, the company continued to repurchase shares aggressively, spending $82.7M on buybacks in the quarter, and total stockholders' equity fell 11.9% from January 31, 2026 to $929.8M, partly due to a $3.7M foreign currency translation loss in the first half.

• · Cash and cash equivalents decreased from $88.4M at Jan 31, 2026 to $83.3M at Jul 31, 2026.
• · Accounts receivable decreased from $166.5M to $122.4M over the same period.
• · Total debt (current and noncurrent) increased from $213.5M to $275.4M.
• · Treasury stock (at cost) increased from $125.6M to $301.9M, reflecting $176.3M in buybacks during the first half of FY27.
• · Accumulated deficit improved from $(375.8M) to $(355.7M).
• · Foreign currency translation loss of $3.7M in H1 FY27 vs. a loss of $0.3M in H1 FY26.
• · Redeemable non-controlling interest increased from $12.7M to $15.4M.

25-08-2026

Renasant Corporation announced the appointment of Catherine Mealor as Executive Vice President and Chief Financial Officer, effective January 1, 2027, succeeding Jim Mabry, who will retire in early 2027. Mabry is expected to be nominated to the Board of Directors at the 2027 Annual Meeting. The company has grown from $14 billion to $27 billion in assets under Mabry's tenure.

• · Catherine Mealor will officially join the company on October 5, 2026, and assume the CFO role on January 1, 2027.
• · Jim Mabry has served as CFO since August 2020 and will step down at the end of 2026, transitioning to retirement in early 2027.
• · The Board intends to nominate Mabry for election as a director at the 2027 Annual Meeting of Shareholders.
• · Mealor has over 20 years of experience in analyzing financial services institutions, most recently at KBW covering small and mid-cap banks in the Southeast.
• · Mealor has served on FASB's Investor Advisory Committee since September 2021 and on the Williams School Board of Advisors at Washington and Lee University.
• · Mealor graduated cum laude from Washington and Lee University with a BS with Special Attainments in Commerce Degree.
• · Mealor will office out of Atlanta, Georgia.

25-08-2026

Datavault AI Inc. (DVLT) received a Nasdaq extension notice on August 25, 2026, granting an additional 180 calendar days, until February 22, 2027, to regain compliance with the $1.00 minimum bid price requirement. The company failed to meet the initial compliance deadline of August 24, 2026, and its stock continues to trade on the Nasdaq Capital Market under the symbol 'DVLT' while it considers options including a potential reverse stock split. However, there is no assurance that compliance will be achieved, and failure to do so could result in delisting.

• · The initial non-compliance letter was received on February 24, 2026, and disclosed in an 8-K filed February 27, 2026.
• · The extension was granted because the company met the continued listing requirement for market value of publicly held shares and all other applicable initial listing requirements except the minimum bid price.
• · The company provided written notice of its intention to cure the deficiency, including by effecting a reverse stock split if necessary.
• · If compliance is not regained by February 22, 2027, Nasdaq will issue a delisting notice, and the company may appeal to a hearings panel, though success is not assured.

25-08-2026

New Found Gold Corp. filed a Form 6-K with the SEC for August 2026, submitting a news release dated August 25, 2026. The filing is a routine foreign issuer report and does not contain any financial results or material operational updates.

25-08-2026

Vipshop Holdings Ltd filed a Form 6-K with the SEC on August 25, 2026, attaching a press release reporting its unaudited second quarter 2026 financial results. The filing includes the company's address in Guangzhou, China, and is signed by CFO Mark Wang. No specific financial figures are disclosed in the filing itself, only the announcement of results.

• · Filing is a Form 6-K for the month of August 2026
• · Commission File Number: 001-35454
• · Address: Vipshop Headquarters, 128 Dingxin Road, Haizhu District, Guangzhou 510220, People's Republic of China
• · The press release (Exhibit 99.1) covers unaudited second quarter 2026 financial results

25-08-2026

ING Groep N.V. filed a Form 6-K with the SEC on August 25, 2026, attaching a press release issued the same day. The filing is a routine foreign issuer report under Rule 13a-16, with no financial results or material business updates disclosed in the 6-K itself.

• · The press release is attached as Exhibit 99.1 but its content is not summarized in the 6-K.
• · The filing is for the month of August 2026 under Commission File Number 001-14642.

25-08-2026

Molecular Partners AG reported an improved net result for H1 2026, with a net loss of CHF 26.7M compared to a net loss of CHF 37.2M in H1 2025, a 28% reduction in year-over-year losses. The company continues to have zero revenue from collaborations and reduced its cash burn, though cash and cash equivalents fell 18% to CHF 67.9M from CHF 82.7M at year-end 2025.

• · The company had zero revenue from research and development collaborations in both H1 2026 and H1 2025.
• · Restructuring expenses were nil in H1 2026 compared to CHF 2.6M in H1 2025.
• · Net finance result swung to positive CHF 0.3M in H1 2026 from a loss of CHF 3.7M in H1 2025, primarily due to the absence of net foreign exchange losses.
• · Basic and diluted net result per share improved to CHF (0.70) in H1 2026 from CHF (1.00) in H1 2025.
• · Cash used in operations decreased to CHF 25.0M from CHF 30.2M, a 17% improvement.
• · Shareholders' equity declined 27% to CHF 58.5M from CHF 80.3M due to the net loss and other comprehensive income items.

25-08-2026

XPENG INC. filed a Form 6-K with the SEC on August 25, 2026, reporting its unaudited financial results for the second quarter of 2026 and interim results for the six months ended June 30, 2026. The filing includes a press release (Exhibit 99.1) and an interim results announcement (Exhibit 99.2). No specific financial figures are provided in the filing itself, only references to the exhibits.

• · Filing type: Form 6-K (Report of Foreign Private Issuer)
• · Filing date: August 25, 2026
• · Commission File Number: 001-39466
• · Exhibit 99.1: Press Release - XPENG Reports Second Quarter 2026 Unaudited Financial Results
• · Exhibit 99.2: Announcement - Interim Results Announcement for the Six Months Ended June 30, 2026
• · Signed by Xiaopeng He, Chairman and CEO

25-08-2026

Equinor ASA disclosed transactions under the third tranche of its 2026 share buy-back programme, covering the week of August 17-21, 2026. During this period, the company repurchased 721,000 shares on the Oslo Stock Exchange (OSE) at a weighted average price of NOK 394.7557, for a total transaction value of NOK 284,618,893.20. Accumulated buy-backs under the tranche now total 2,928,004 shares at a weighted average price of NOK 384.9271, with a total value of NOK 1,127,068,112.50. The daily volume declined from 148,000 to 140,000 shares over the week, while the weighted average price rose from NOK 387.7655 to NOK 399.4722.

• · All transactions were executed on the Oslo Stock Exchange (OSE); no activity on CEUX or TQEX.
• · Daily weighted average share price ranged from NOK 387.7655 to NOK 399.4722 during the week.
• · Previously disclosed buy-backs under the tranche: 2,207,004 shares at a weighted average price of NOK 381.7162.

25-08-2026

Navitas Semiconductor announced a definitive agreement to acquire Claros, a power management solutions company developing VPD and IVR technology for AI data centers, in a transaction valued up to approximately $232.8 million. The acquisition is expected to extend Navitas' grid-to-xPU high-power portfolio, double its 2030 serviceable addressable market to over $8 billion, and strengthen its AI infrastructure strategy under Navitas 2.0. However, the company does not expect a material change to its profitability timeline, and the transaction is subject to customary closing conditions and regulatory approvals.

• · The transaction has been unanimously approved by the boards of both companies.
• · Closing expected before year-end 2026, subject to customary conditions and regulatory approvals.
• · Claros was founded in 2024 and is backed by Red Cell Partners, General Catalyst, Systemiq Capital, VIPC, and other investors.
• · Navitas has over 300 patents issued or pending and is CarbonNeutral®-certified.
• · The acquisition adds at least $3.5 billion from VPD and IVR markets to Navitas' SAM.
• · Navitas' short-to mid-term financial model and path to profitability remain unchanged.

25-08-2026

HDFC Bank Ltd filed a Form 6-K with the SEC for the month of August 2026, as a routine foreign private issuer report. The filing includes a disclosure exhibit (Exhibit 99) but no specific financial results, material events, or period-over-period comparisons are provided in the filing content. The report is a procedural compliance filing with no substantive business updates.

• · Filing is a Form 6-K for the month of August 2026 under the Securities Exchange Act of 1934.
• · Commission File Number: 001-15216.
• · Registrant's address: HDFC Bank House, Senapati Bapat Marg, Lower Parel, Mumbai 400 013, India.
• · The registrant indicates it files annual reports under Form 20-F.
• · Exhibit 99 is referenced as 'Disclosure' but no content is provided in the filing text.

25-08-2026

Dominion Energy filed an 8-K supplementing its definitive proxy statement related to its pending merger with NextEra Energy. The company disclosed it has received demand letters and two shareholder lawsuits alleging disclosure deficiencies in the proxy statement, which Dominion Energy believes are without merit but is voluntarily providing supplemental disclosures to avoid delays. The supplemental disclosures include additional details on the background of the merger and financial analyses performed by NextEra Energy's financial advisor, Lazard.

• · Special meeting of shareholders to vote on the merger is scheduled for September 3, 2026.
• · The two shareholder lawsuits are: Scott v. Dominion Energy, Inc., et al., Index No. 654722/2026 (N.Y. Sup. Ct.) and Clark v. Dominion Energy, Inc., et al., Index No. 654742/2026 (N.Y. Sup. Ct.).
• · The lawsuits allege negligent misrepresentation, concealment, and negligence under New York law.
• · Plaintiffs seek injunctive relief, actual and punitive damages, attorneys' fees, and expenses.
• · Supplemental disclosures include details on the non-disclosure and standstill agreement with Party A executed on March 27, 2026.
• · Lazard's sum-of-the-parts DCF analysis for NextEra Energy used discount rate ranges based on WACC and exit multiples based on professional judgment.
• · Lazard's comparable company analysis for NextEra Energy's Premium Utility Peers showed 2026E P/E multiples ranging from 18.4x (CMS Energy) to 24.8x (Entergy), with a mean of 20.5x and median of 20.0x.
• · For NextEra Energy's Premium Independent Power Producer Peers, 2026E EV/EBITDA multiples ranged from 10.7x (Clearway) to 13.7x (Constellation), with a mean of 12.6x and median of 13.3x.
• · For Dominion Energy's Utility Peers, 2026E P/E multiples ranged from 14.4x (Eversource) to 20.2x (Southern Company), with a mean of 18.5x and median of 18.1x.
• · For Dominion Energy's Premium Independent Power Producer Peers, 2026E EV/EBITDA multiples ranged from 10.7x (Clearway) to 13.7x (Constellation), with a mean of 12.6x and median of 13.3x.

25-08-2026

Nayax Ltd. announced on August 25, 2026, that it has entered into a definitive agreement to acquire IPS Group, a leading smart parking technology provider. The acquisition is disclosed via a press release and an investor presentation filed as exhibits to this Form 6-K. No financial terms or performance metrics are provided in this filing.

• · The acquisition was announced via a press release and a presentation titled 'Acquisition of IPS Group'.
• · The filing is a Form 6-K for the month of August 2026.
• · The press release and presentation are furnished as exhibits and not deemed filed under the Exchange Act.

25-08-2026

Stran & Company, Inc. held its 2026 Annual Meeting on August 24, 2026, with 72.22% of outstanding shares represented, forming a quorum. Stockholders elected all six director nominees and ratified the appointment of CBIZ CPAs P.C. as the independent auditor for fiscal year 2026. All proposals passed with overwhelming support, though director Andrew Stranberg received the highest number of withheld votes (867,013) among the nominees.

• · The record date for the meeting was June 29, 2026.
• · There were no abstentions or against votes for the director election proposal.
• · The ratification of CBIZ CPAs P.C. received 13,458,300 votes for, 3,001 against, and 221 abstentions, with no broker non-votes.
• · Andrew Stranberg received the highest number of withheld votes (867,013), representing about 6.9% of votes cast for directors.
• · The company is an emerging growth company and has elected not to use the extended transition period for complying with new or revised financial accounting standards.

25-08-2026

Identiv, Inc. filed a DEFA14A proxy statement on August 25, 2026, disclosing that a shareholder lawsuit challenging the 'Proportional Voting Above Threshold' provision of the Governance Letter Agreement has been mooted by a prior filing. Other issues raised in the complaint remain under review, indicating ongoing litigation risk.

• · The DEFA14A was filed with the SEC on August 24, 2026.
• · The plaintiff's concerns about the 'Proportional Voting Above Threshold' provision have been mooted.
• · Other issues raised by the complaint remain under review.

25-08-2026

Barinthus Biotherapeutics plc notified Nasdaq of its intent to withdraw its American Depositary Shares (ADSs) from listing, effective with a scheme of arrangement under the UK Companies Act expected to close on September 3, 2026. The delisting is part of a merger with Clywedog Therapeutics, after which the combined entity will be renamed Clywedog Therapeutics Holdings, Inc. and list on Nasdaq under the ticker 'CLYD'. The Scheme Exchange Ratio was set at 0.111 to satisfy Nasdaq's minimum price requirement for the new listing.

• · Trading of ADSs on Nasdaq is expected to halt prior to the opening of trading on September 3, 2026.
• · The company will file a Form 15 with the SEC to deregister the ADSs and suspend reporting obligations under Sections 13 and 15(d) of the Exchange Act.
• · The court hearing for the scheme is scheduled for September 1, 2026 at the Royal Courts of Justice, London.
• · The Merger Exchange Ratio will be determined immediately prior to closing based on the Scheme Exchange Ratio and adjustments in the Merger Agreement to maintain the agreed ownership split.

25-08-2026

Artificial Intelligence Technology Solutions Inc. (AITX) filed an 8-K on August 25, 2026, announcing a press release from its subsidiary PURSUON regarding a growing ROAMEO deployment pipeline and expanded production readiness, with a stated goal of 50 units by August 2027. The filing is a routine update and does not contain financial results or negative performance metrics.

• · The press release is attached as Exhibit 99.1 and is furnished, not filed, under the Exchange Act.
• · The company's principal executive offices are located at 10800 Galaxie Avenue, Ferndale, Michigan.

25-08-2026

Escalade, Inc. acquired substantially all the assets of ASL Solutions, Inc. on August 24, 2026, as disclosed in an 8-K filing and accompanying press release. The company explicitly states that the transaction is not material for financial reporting purposes, as it does not involve a significant amount of assets. No financial terms or period-over-period comparisons were disclosed.

• · The acquisition closed on August 24, 2026.
• · The press release announcing the acquisition was issued on August 25, 2026 (attached as Exhibit 99.1).
• · The transaction is described as 'not material' and does not involve a significant amount of assets.

25-08-2026

QDM International Inc. filed Amendment No. 6 to its S-1 registration statement for a firm commitment public offering of common stock, targeting up to $15,000,000. The company's common stock is currently quoted on the OTCQB under the symbol 'QDMI' at a last reported price of $5.50 per share as of August 21, 2026, and it has applied to list on Nasdaq under the symbol 'QDMI'. CEO Huihe Zheng holds approximately 99.2% of voting power, creating significant governance concentration risk, and the company faces substantial legal and operational risks from its Hong Kong-based operations and potential PRC regulatory actions.

• · The company is a Florida holding company with no subsidiaries or operations in mainland China; its operating subsidiary is in Hong Kong.
• · The company does not believe it is required to file with or obtain approval from the CSRC for this offering, based on its current structure and operations.
• · The offering price will be determined between the underwriters and the company at pricing and may be at a discount to the current market price.
• · The company is a 'smaller reporting company' and has elected to comply with reduced public company reporting requirements.
• · The company has applied to list on Nasdaq but no assurance can be given that the application will be approved.
• · The company has no VIE structure and does not plan to establish one.

25-08-2026

Arcturus Therapeutics presented a poster on its ARCT-810 mRNA therapy for Ornithine Transcarbamylase (OTC) deficiency at the 2026 SSIEM Annual Symposium in Helsinki, Finland. The presentation includes data on dietary intake and biochemical markers in adolescents and adults. Additional data and the regulatory plan for the program are expected later this quarter. No financial figures or period-over-period comparisons were disclosed in this filing.

• · Poster titled 'Impact of ARCT-810 mRNA Therapy on Dietary Intake and Biochemical Data in Adolescents and Adults with Ornithine Transcarbamylase Deficiency' presented at the 2026 Annual Symposium of the Society for the Study of Inborn Errors of Metabolism (SSIEM) in Helsinki, Finland.
• · Additional data and regulatory plan for ARCT-810 expected to be communicated later this quarter (Q3 2026).

25-08-2026

PicPay Holdings Netherlands B.V. reported strong Q2 2026 results with net revenue of R$4.1 billion, up 67% YoY, and adjusted net income of R$283 million, up 135% YoY. Gross profit rose 48% YoY to R$1.2 billion, and net interest income (NII) grew 65% YoY to R$2.0 billion. Average revenue per active customer (ARPAC) increased 52% YoY to R$92.0, while cost to serve remained low at R$21.3 per active client, and return on equity (ROE) reached 20.2%.

• · Cost to serve per active client was R$21.3, which is less than one-fourth of ARPAC (R$92.0).
• · ROE for Q2 2026 was 20.2%.
• · Derivatives and hedge accounting revenues of R$391 million were excluded from total revenue and financial income for the NII calculation.
• · NIM from credit products is calculated as margin from credit products multiplied by four, divided by the average total credit portfolio.
• · Loss Absorption represents all expected losses over the lifetime credit-related revenues of a given credit concession.

25-08-2026

Camac Fund, LP and its subsidiary Zodiac Partners II, LLC filed an amended tender offer (SC TO-T/A) to acquire shares of DXL (Destination XL Group). As of March 9, 2026, there were 54,810,511 shares outstanding, with approximately 44,000 stock options and 1,259,000 restricted stock units outstanding as of January 31, 2026. The filing includes an indicative $75 million revolving credit facility term sheet and multiple press releases, indicating an active and evolving acquisition process.

• · The filing is an amendment (SC TO-T/A) to a tender offer, originally filed on March 19, 2026.
• · Multiple press releases were issued by Zodiac Partners II, LLC on May 12, May 21, June 12, June 23, July 27, and August 24, 2026.
• · An amended equity commitment letter between Zodiac Partners II, LLC and Camac Fund LP was dated June 22, 2026.
• · The offer includes an indicative $75 million revolving credit facility term sheet (confidential treatment requested for certain portions).

25-08-2026

VersaBank filed a Form 6-K with the SEC on August 25, 2026, reporting the issuance of a Reorganization Agreement and an Abridgement Certificate on August 24, 2026. The filing is a routine foreign private issuer report and does not contain any financial results or operational metrics.

• · The filing is furnished under Form 6-K and is not deemed filed under Section 18 of the Exchange Act.
• · The Reorganization Agreement and Abridgement Certificate are attached as Exhibits 99.1 and 99.2, respectively.
• · The report was signed by Tammie Ashton, Global Executive Vice President.